Family Planning

Page updated: August 2020

Federal resources are available to support the Medi-Cal program in the area of family planning. For this reason, it is most important that family planning services provided to Medi-Cal recipients be identified by entering the appropriate family planning indicator on the claim form.

Participation and Services

Family planning services are provided to individuals of childbearing age to enable them to determine the number and spacing of their children, and to help reduce the incidence of maternal and infant deaths and diseases by promoting the health and education of potential parents. They include the following:

- Medical and surgical services performed by or under the direct supervision of a licensed physician
- Laboratory and radiology procedures, drugs and devices prescribed by a licensed physician

Participation

Participation must be voluntary and individuals must not be coerced to accept services. Family planning services shall not be required for receipt of any welfare benefits. Individuals must not be coerced to employ or not to employ any particular method of birth control including sterilization and abortion. Sterilization services are subject to special program requirements, including a minimum age, informed consent process, and waiting period. (Refer to the *Sterilization* section in the appropriate Part 2 manual for detailed information regarding consent for sterilization.)

Services

Family planning services include, but are not limited to:

- Patient visits for the purpose of family planning
- Family planning counseling services provided during a regular patient visit (see "Non-Comprehensive Family Planning Visits" later in this section)
- IUD and IUCD insertions, or any other invasive contraceptive procedures/devices
- Tubal ligations
- Vasectomies
- Contraceptive drugs or devices
- Treatment for complications resulting from previous family planning procedures
- Laboratory procedures, radiology and drugs associated with family planning procedures

Some of these services can be easily recognized as family planning by the CPT® procedure code or drug type code (for example, intrauterine device (IUD) insertion, vasectomy, contraceptive drugs and devices). Other services such as visits, laboratory tests and X-rays are not so readily identifiable as family planning services.

Billing

Providers are to indicate "Family Planning" as a diagnosis when billing any of the services listed on a previous page that relate to family planning. Indicate this by entering the appropriate code in the *Conditions Codes* fields (Boxes 18-24) of the *UB-04* claim form or in the *EPSDT/Family Planning* field (Box 24H) on the *CMS-1500* claim. Complete the diagnosis code or the appropriate narrative, where applicable. (Refer to the billing instructions in the *CMS-1500 Completion* or *UB-04 Completion: Outpatient Services* section in this manual for family planning codes and descriptions.) In addition, providers should identify services related to the treatment of complications of family planning.

Examples:

- Surgical procedure such as I & D (incision and drainage) of pelvic abscess resulting from infection with IUD
- Office visit and laboratory tests needed because of uterine bleeding while on oral contraceptives

Occasionally other services (including hospital, radiology, pharmaceutical, blood and blood derivatives) may be related to family planning or to its complications, and should be properly identified.

Page updated: April 2022

Physician-Administered Drugs: Inclusion of NDC on Claim

For physician-administered drugs, providers must include the National Drug Codes (NDCs) on the claim, according to the policy in the <u>Physician-Administered Drugs – NDC</u> section in this manual. This is in addition to the HCPCS code, which remains the basis of pricing. For claim form completion instructions, refer to the <u>Physician-Administered Drugs – NDC:</u> <u>CMS-1500 Billing Instructions</u>, or <u>Physician-Administered Drugs – NDC: UB-04 Billing Instructions</u> sections in the appropriate Part 2 manual.

Reimbursement Rates Onsite Dispensing

«The maximum reimbursement rates for items dispensed onsite are set by the Medi-Cal program and are contained in the Medi-Cal rate table, which may be accessed on the Medi-Cal Rates page of the Medi-Cal Providers website.
»

For injections, the price listed on the Medi-Cal Rates page includes the one-time administration fee of \$4.46 for the first billed unit. Since the administration fee is paid only once for each drug administered, subsequent units claimed must have the administration fee subtracted from the published rate.

Providers participating as Public Health Service (PHS) entities, and purchasing drugs through the PHS 340B program, must not bill more than the actual acquisition cost of the drug, as charged by the manufacturer at a price consistent with the PHS program for covered outpatient drugs. Drugs subject to the PHS program must be billed with modifier UD in accordance with Medi-Cal policy.

Eligible entities, pursuant to Section 14132.01 of California *Welfare and Institutions Code* (W&I Code), may also bill a clinic dispensing fee and an administration fee, if applicable, as defined below.

Eligible entities will be reimbursed the lesser of the acquisition cost of the drug plus the maximum dispensing fee or the Medi-Cal maximum rate on file.

«Pursuant to Section 14132.01 of the W&I Code, eligible entities may bill for a dispensing fee of \$12 per unit for the following products:»

Page updated: September 2025

Intrauterine Contraception/Intrauterine Devices

| HCPCS Code | Description | |
|------------|---|--|
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system (kyleena), | |
| | 19.5 mg | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), | |
| | 52 mg | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), | |
| | 52 mg | |
| J7300 | Intrauterine copper contraceptive | |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), | |
| | 13.5 mg | |

Subdermal Contraceptive Implant

| HCPCS Code | Description | | |
|------------|---|--|--|
| J7307 | Etonogestrel (contraceptive) implant system, including implant supplies | | |

The clinic dispensing fee unit for J7296, J7297, J7298, J7300, J7301 and J7307 is a calendar month, with a maximum allowable of 36 units per device.

Medroxyprogesterone Acetate

| HCPCS Code | Description | | |
|-------------------|--|--|--|
| ‹‹J3490 | Medroxyprogesterone acetate, 104mg/0.65ml SQ>> | | |
| ‹‹J3490 U8 | Medroxyprogesterone acetate, 150 mg/ml IM>> | | |

Page updated: October 2022

Oral Contraceptives, Vaginal Ring and Transdermal Patch

| HCPCS Code | Description |
|------------|--|
| J7294 | Segesterone acetate and ethinyl estradiol 0.15 mg, 0.013 mg per |
| | 24 hours; yearly vaginal system, each |
| J7295 | Ethinyl estradiol and etonogestrel 0.015 mg, 0.12 mg per 24 hours; |
| | monthly vaginal ring, each |
| J7304U1 | Contraceptive supply, hormone containing patch, each (norelgestromin |
| | and ethinyl estradiol transdermal system) |
| J7304U2 | Contraceptive supply, hormone containing patch, each (levonorgestrel |
| | and ethinyl estradiol transdermal system) |
| S4993 | Contraceptive pills for birth control |

The clinic dispensing fee unit for S4993 is a calendar month, with a maximum allowable of 13 units. The clinic dispensing fee unit for J7294 and J7295 is a calendar month with a maximum allowable of 12 units. The clinic dispensing fee unit for J7304U1 and J7304U2 is a calendar month, for three patches dispensed with a maximum allowable of 12 units.

Pursuant to Section 14132.01 of W&I Code, eligible entities may bill for a dispensing fee of \$17 per unit for emergency contraception:

| HCPCS Code | Description |
|------------|---|
| J3490U5 | Ulipristal acetate, 30 mg |
| J3490U6 | < <levonorgestrel 1.5="" mg="" of="" one="" tablet="">></levonorgestrel> |

The clinic dispensing fee unit for J3490 U5 and J3490 U6 is one pack per recipient per month with a maximum allowable of 1 unit.

Other Contraceptive Supplies

For other contraceptive supplies or medications, billed with HCPCS codes (A4261, A4266, A4267, A4268, A4269U1, A4269U2, A4269U3, A4269U4, A4269U5 and S5199), the clinic dispensing fee is 10 percent of the subtotal.

Non-Comprehensive Family Planning Visits

Modifier FP should be used when billing for additional time spent discussing family planning needs with a recipient during routine, non-family planning office visits. Family planning counseling services include the following:

- Contraceptive counseling
- Instruction in pregnancy prevention
- Any other family planning counseling service

«Modifier FP may be used with the following HCPCS and CPT codes: Z1032 thru Z1038, Z6200 thru Z6500, 59400, 59510, 59610, 59618, 99202 thru 99215, 99242 thru 99245, 99281 thru 99285, 99341, 99342 and 99344 thru 99353, 99384, 99394, and 99417.»

Reimbursement is available to individuals of childbearing age. Additional reimbursement is made for appropriate use of this modifier, but not more than once per recipient, for the same provider, in a 12-month period. Services billed by an assistant surgeon or anesthesiologist are not reimbursable.

Modifier FP must be billed on a separate claim line than the primary visit code. When billing for family planning counseling, list the primary procedure code and modifier, if applicable, on one claim line, and the same procedure code with modifier FP on the next claim line. A family planning diagnosis code is not required when billing with this modifier.

Note: Modifier FP should not be billed with comprehensive family planning visit as identified by the family planning diagnosis code.

See "Comprehensive Family Planning Visit" in this section when billing for visits primarily related to family planning.

Services Not Included in Family Planning

Reimbursement for family planning does not extend to the following services:

- Facilitating services such as transportation, parking, and childcare while family planning care is being obtained
- Infertility studies or procedures provided for the purpose of diagnosing or treating infertility
- Reversal of voluntary sterilization
- Hysterectomy for sterilization purposes only
- Therapeutic abortions and related services
- Spontaneous, missed or septic abortions and related services

Comprehensive Family Planning Visits

The following ICD-10-CM diagnosis codes, when billed as a primary diagnosis code, indicate comprehensive family planning services. The use of these codes enables federal financial participation in funding these services.

<Table of ICD-10-CM Codes that When Used as Primary ICD-10 Indicate Service is a Family Planning Service>>

| ICD-10-CM Code | Description | | |
|-------------------|---|--|--|
| Z30.011 | Encounter for initial prescription of contraceptive pills | | |
| Z30.012 | Encounter for prescription of emergency contraception | | |
| Z30.013 | Encounter for initial prescription of injectable contraceptive | | |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive | | |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device | | |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive | | |
| Z30.018 | Encounter for initial prescription of other contraceptives (initiate use of | | |
| | contraceptive patch, vaginal ring or implant) | | |
| Z30.02 | Counseling and instruction in natural family planning to avoid pregnancy | | |
| Z30.09 | Encounter for other general counseling and advice on contraception | | |
| Z30.2 | Encounter for sterilization | | |
| Z30.41 | Encounter for surveillance of contraceptive pills | | |
| Z30.42 | Encounter for surveillance of injectable contraceptive | | |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device | | |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device | | |
| Z30.432 | Encounter for removal of intrauterine contraceptive device | | |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device | | |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device | | |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device | | |

| ICD-10-CM | Description | | |
|-----------|---|--|--|
| Code | | | |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive | | |
| Z30.46 | Encounter for checking, reinsertion or removal of implantable subdermal contraceptive | | |
| Z30.49 | Encounter for surveillance of other contraceptives | | |
| Z30.49 | Encounter for surveillance of barrier contraception | | |
| Z30.49 | Encounter for surveillance of diaphragm | | |
| Z31.430 | Encounter of female for testing for genetic disease carrier status for | | |
| | procreative management | | |
| Z31.438 | Encounter for other genetic testing of female for procreative management | | |
| Z31.440 | Encounter of male for testing for genetic disease carrier status for | | |
| | procreative management | | |
| Z31.441 | Encounter for testing of male partner of patient with recurrent pregnancy | | |
| | loss | | |
| Z31.5 | Encounter for procreative genetic counseling | | |
| Z97.5 | Presence of (intrauterine) contraceptive device | | |
| Z98.51 | Tubal ligation status | | |
| Z98.52 | Vasectomy status | | |

Contraceptives

Contraceptive medication and supplies for family planning services billed by providers such as family planning centers include the following:

«Table of HCPCS Codes for Contraceptive Medications and Supplies»

| HCPCS Code | Description |
|-------------------|--|
| J7294 | Segesterone acetate and ethinyl estradiol 0.15 mg, 0.013 mg per |
| | 24 hours; yearly vaginal system, each |
| J7295 | Ethinyl estradiol and etonogestrel 0.015 mg, 0.12 mg per 24 hours; |
| | monthly vaginal ring, each |
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system (kyleena) 19.5 mg |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), |
| | 52 mg |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), |
| | 52 mg |
| J7300 | Intrauterine copper contraceptive |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), |
| | 13.5 mg |
| J7304U1 | Contraceptive supply, hormone containing patch, each (norelgestromin |
| | and ethinyl estradiol transdermal system) |
| J7304U2 | Contraceptive supply, hormone containing patch, each (levonorgestrel |
| | and ethinyl estradiol transdermal system) |
| S4993 | Contraceptive pills for birth control |

Providers must document the medical necessity for billing repeat IUC/IUD placement of the same device within the device's duration of use, as noted by the label, in the *Remarks* field (Box 80)/*Additional Claim Information* field (Box 19) of the claim.

The number of cycles covered (up to 18) is entered in the *Service Units/Days or Units* field (Box 24G) of the claim when billing for code S4993. The quantity dispensed is entered in the *Service Units/Days or Units* field (Box 24G) of the claim when billing for J7294 (1 vaginal ring), J7295 ((up to 18 vaginal rings)) and when billing for J7304U1 or J7304U2 ((up to 54 patches)). The maximum quantity is intended for clients on continuous cycle. A 12-month supply of the same product of J7294, J7295, J7304U1 or J7304U2 or S4993 may be dispensed twice in one year. A *Treatment Authorization Request* (TAR) is required for the third supply of up to 12 months of the same product of J7294, J7295, J7304U1, J7304U2 or S4993 requested within a year.

Page updated: October 2022

Codes J7294, J7295, J7304U1, J7304U2, and S4993 may be dispensed by a registered nurse (RN) who has completed the required training pursuant to California *Business and Professions Code* (B&P Code), Section 2725.2, when Evaluation and Management (E&M) procedure CPT codes 99202, 99211 or 99212 (office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making) is performed. If performed by an RN, the E&M procedures must be billed with modifier TD.

Emergency Contraceptive: Ella

Ella (ulipristal acetate, 30 mg) is billed with HCPCS code J3490U5 (modifier U5 must be used with code J3490). Ella contains one pill per package. This contraceptive is for females only and is a single course of treatment to be taken within five days (120 hours) of unprotected sex and can reduce the risk of pregnancy by 85 percent after unprotected sex or a contraceptive accident, such as a condom breaking. Ella is recommended for women with a body mass index (BMI) over 25.

Emergency Contraceptive: Next Choice

«Next Choice (levonorgestrel one tablet of 1.5 mg) is billed with HCPCS code J3490U6 (modifier U6 must be used with code J3490). Next Choice contains one progestin-only pill containing levonorgestrel 1.5 mg.» This contraceptive is for females only and is a single course of treatment to be taken within three days (72 hours) of unprotected sex and can reduce the risk of pregnancy by 89 percent after unprotected sex or a contraceptive accident, such as a condom breaking.

Combined Maximum Dispensing

Codes J3490U5 and J3490U6 have a combined maximum dispensing. They may be reimbursed up to a maximum of one pack per recipient, per month, any provider and a maximum of six packs per recipient, per year, any provider.

Codes J3490U5 and J3490U6 may be dispensed by an RN who has completed the required training pursuant to California B&P Code, Section 2725.2, when E&M procedure codes 99202, 99211 or 99212 (office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making) is performed. If performed by an RN, the E&M procedures must be billed with modifier TD.

Page updated: April 2025

Implantable Contraceptives: Etonogestrel

«Etonogestrel, 68 mg contraceptive implant (Nexplanon) is billed with code J7307. The implant must be FDA-approved, labeled for use in the United States, and obtained from the single-source distributor. Only providers who have completed a company-sponsored training course may purchase the implant». The certificate of training for each provider who inserts the implant must be retained by the provider and is subject to post-audit review.

«The implant may be reimbursed when service is performed by non-physician medical practitioners (NMPs) who have completed the required training. The implant is not reimbursable to Pharmacy providers.

»

Providers must maintain a written log or electronic record of all Implanon implant systems, including the recipient's name, medical record or Medi-Cal Benefits Identification Card (BIC) number, date of surgery, and lot number of the product, for at least three years from the date of insertion. Records are subject to post-audit reviews.

Implantable Contraceptives: Billing Guidelines

When billing for HCPCS code J7307, providers must attach a copy of the invoice to the claim or document the invoice number and price in the *Remarks* field (Box 80)/*Additional Claim Information* field (Box 19) of the claim.

Etonogestrel (code J7307)

- · Covered for females
- Bill in conjunction with ICD-10-CM diagnosis code Z30.017 for initiation and Z30.46 for surveillance

Providers must document the medical necessity for billing repeat implant placement within the device's duration of use, as noted by the label, in the *Remarks* field (Box 80)/*Additional Claim Information* field (Box 19) of the claim.

Implantable Contraceptives: Surgical Insertion

The following CPT codes are used for billing and reimbursement of the surgical procedure to insert or remove the contraceptive:

| CPT Code | Description |
|----------|---|
| 11976 | Removal, implantable contraceptive capsules |
| 11981 | Insertion, drug-delivery implant (i.e., bioresorbable, biodegradable, |
| | non-biodegradable) |

When multiple surgery procedures are performed at the same operative session, see the *Surgery: Billing with Modifiers* section of the provider manual.

These are common office procedures that require "By Report" documentation and can be reimbursed as a physician, PA and Certified Nurse Midwife.

Anesthetic Injection Codes

Anesthetic injection codes are reimbursable when anesthesia is necessary during insertion or removal of implantable contraceptive capsules.

Injectable Contraceptives

HCPCS code J3490U8 (unclassified drugs) is limited to contraceptive injections and is reimbursable not more frequently than once every 80 days if billed by the same provider, for the same recipient.

Note: Modifier U8 must be used with code J3490 to indicate the intramuscular Medroxyprogesterone acetate injection

Medroxyprogesterone acetate 150 mg is administered by intramuscular injection every three months. Code J3490U8 may be administered by an RN who has completed the required training pursuant to California B&P Code, Section 2725.2, when E&M procedure codes 99202, 99211 or 99212 (office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making) is performed. If performed by an RN, the E&M procedures must be billed with modifier TD.

«Medroxyprogesterone acetate 104mg is self-administered by the client via subcutaneous injection. The initial dose is to be administered by the client in the clinic, for the purpose of client education for future doses. Subsequent doses are to be dispensed by a pharmacy. Code J3490 may be administered by an RN who has completed the required training pursuant to California B&P Code, Section 2725.2, when E&M procedure codes 99202, 99211 or 99212 (office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making) is performed. If performed by an RN, the E&M procedures must be billed with modifier TD.»

Page updated: October 2021

HCPCS Codes for Drugs and Supplies Dispensed Onsite

The HCPCS codes for drugs and supplies dispensed in clinics are as follows:

| HCPCS Code | Description |
|---|------------------------------------|
| A4261 | Cervical cap for contraceptive use |
| A4266 | Diaphragm for contraceptive use |
| A4267 | Condom, male |
| A4268 | Condom, internal |
| A4269 | Contraceptive supply, spermicide |
| A4269U1 | Gel/jelly/foam/cream |
| A4269U2 | Spermicidal suppositories |
| A4269U3 | Spermicidal vaginal film |
| A4269U4 | Contraceptive sponge |
| < <a4269u5< td=""><td>Vaginal gel>></td></a4269u5<> | Vaginal gel>> |
| S5199 | Lubricant |

Basal temperature thermometers are dispensed at Medi-Cal participating pharmacies with a prescription.

Note: << A4269 is billed with modifiers U1, U2, U3, U4 or U5 to indicate the type of contraceptive spermicide or non-spermicidal vaginal gel.>>

On claims for HCPCS codes A4267, A4269U1, A4269U2, A4269U3, A4269U4, «A4269U5» and S5199, providers must document the following in the *Remarks* field (Box 80) or *Additional Claim Information* field (Box 19):

- · Description of items
- Actual quantity
- "At cost" expense
- Clinic dispensing fee, if applicable

Providers enter the appropriate code in the *Condition Codes* fields (Boxes 18 thru 24) on the *UB-04* claim form or in the *EPSDT/Family Planning* field (Box 24H) on the *CMS-1500* claim form. Providers also include the appropriate diagnosis when billing these codes.

Page updated: October 2021

HCPCS codes A4267, A4268, A4269U1, A4269U2, A4269U3, A4269U4, <A4269U5>> and S5199 must be listed on separate claim lines.

«If any of the following codes A4267, A4269U1, A4269U2, A4269U3, A4269U4 and S5199 or any combination of the codes is present on a claim, the total maximum allowable amount for any or all is \$14.99. When billing for contraceptive supplies (A4267, A4269U1, A4269U2, A4269U3, A4269U4 or S5199) dispensed for the same patient by the same provider, the minimum interval between dispensing events is 15 days.»

HCPCS code A4268 may be dispensed up to 12 units per claim and up to 24 units in a 90-day period.

«HCPCS code A4269U5 is restricted to one box (12 single-use applicators) per dispensing and limited to three dispensings per any 75-day period.

For HCPCS codes A4261 and A4266, providers must document the following in the *Remarks* field (Box 80) or *Additional Claim Information* field (Box 19) of the claim:

- Description of items and type of diaphragm
- "At cost" expense
- Clinic dispensing fee, if applicable

Note: Neither HCPCS code Z7610 nor CPT code 99070 is used to bill for contraceptive supplies or medications.

Contraceptive Supplies

Contraceptive supplies may be billed by all Medi-Cal providers. Covered supplies include FDA-approved cervical cap contraceptive (A4261), diaphragm (A4266), male condoms (A4267), internal condoms (A4268), spermicides (A4269U1, A4269U2, A4269U3 or A4269U4), «vaginal gel (A4269U5)» and lubricants (S5199).

Evaluation and Management Codes

E&M CPT codes, for example 99203 or 99213, may be billed when the patient is counseled regarding contraception or is examined to determine the suitability of contraceptive modalities.

Modifiers UA and UB

Modifier UA (supplies and drugs for surgical procedures without general anesthesia) or UB (supplies and drugs for surgical procedures with general anesthesia) is reimbursable with CPT code 11976 (removal of implantable contraceptive capsules), code 58300 (insertion of an IUD) and code 58301 (removal of an IUD) when surgical supplies are necessary.

Elective Sterilization

Please refer to the *Sterilization* section in the appropriate Part 2 manual for billing instructions.

Family Planning-Related Services

Family planning-related services are medical diagnosis and treatment services that are provided pursuant to a family planning service in a family planning setting.

Miscellaneous Drugs

Miscellaneous drugs for non-surgical procedures are billed with HCPCS codes S5000 (prescription drug, generic) or S5001 (prescription drug, brand name). These codes may be used only by hospital outpatient departments, emergency rooms, surgical clinics and community clinics.

For a list of reimbursable drugs that may be billed with HCPCS codes S5000 or S5001, refer to the table in the *Drugs: Onsite Dispensing Price Guide* section in the Family PACT manual. The table lists the acceptable size and/or strength of each reimbursable drug, maximum billing units per claim, rate per unit, maximum drug cost, clinic dispensing fee, upper payment limit and fill frequency (days).

Page updated: May 2025

Calculating Total Charges

The following information must be entered in the *Remarks* field (Box 80) of the *UB-04* or an attachment:

- Enter the name of the drug or supply (from the <u>Drugs: Onsite Dispensing Price Guide</u> section of the Family PACT manual) and the size and/or strength, if applicable (for example, 300 mg tablets).
- Multiply the number of units dispensed by the Medi-Cal rate per unit to obtain the drug cost, add the clinic dispensing fee (if applicable), then enter the total for the claim line.
- Each listed regimen is considered to be one (service) unit, regardless of the number of tablets contained in the regimen.

For claim form examples, refer to the <u>Family Planning Billing Example: UB-04</u> section in the <u>Outpatient Services</u> – <u>Clinics and Hospitals</u> provider manual.

If multiple drugs are billed using code S5000 or S5001, the billing code can be repeated on additional claim lines with the appropriate National Drug Code (NDC).

ICD-10-CM Diagnosis Codes Used with S5000 and S50001

Claims billed with HCPCS code S5000 or S5001 must include two ICD-10-CM diagnosis codes: the covered family planning-related ICD-10-CM diagnosis code along with the family planning diagnosis, listed below, for which the client is being seen. Only one family planning-related ICD-10-CM diagnosis code must be entered per claim.

| Z30.011 | Z30.017 | Z30.41 | Z30.432 | Z30.46 |
|---------|---------|-------------|---------|--------|
| Z30.013 | Z30.018 | Z30.42 | Z30.433 | Z30.49 |
| Z30.015 | Z30.02 | Z30.430 | Z30.44 | Z98.51 |
| Z30.016 | Z30.2 | ‹‹Z30.431›› | Z30.45 | Z98.52 |

If a combination of drug regimens is billed with a single family planning-related ICD-10-CM diagnosis code, the drug regimens should be entered on separate claim lines.

If two or more drugs are dispensed with different family planning-related ICD-10-CM diagnosis codes, then a separate claim must be submitted for each ICD-10-CM diagnosis code and corresponding drug(s).

The family planning-related ICD-10-CM diagnosis codes and corresponding drugs that are reimbursable are listed in the following tables.

<u>Family Planning-Related Services: Management of Sexually Transmitted Infections (STIs)</u>

Treatment or diagnostic testing of specified STIs may be provided as clinically indicated.

Partner Exposed to Chlamydia, Gonorrhea, Syphilis, Trichomoniasis

| ICD-10-CM Code | Description | Medications + |
|----------------|---------------------------------------|---------------|
| Z20.2 | Use Z20.2 for diagnosis and treatment | N/A |
| | of an asymptomatic partner exposed to | |
| | active case of chlamydia, gonorrhea, | |
| | syphilis, or trichomoniasis (M/F) | |

Chlamydia

| ICD-10-CM Code | Description | Medications + |
|----------------|-------------------------------------|----------------------------|
| A56.01 | CT cystitis and urethritis (M/F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| A56.09 | Other chlamydial infection lower of | Azithromycin, Doxycycline, |
| | genitourinary tract (F) | ‹‹Levofloxacin›› |
| A56.3 | CT anus/rectum (M/F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| A56.4 | N/A | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |

Presumptive DX (Chlamydia)

| ICD-10-CM Code | Description | Medications + |
|----------------|--|----------------------------|
| N34.2 | Other urethritis (M) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| N45.3 | Epididymo-orchitis (M) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| N72 | Inflammatory disease of cervix uteri (F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| N89.8 | Other specified non-inflammatory | Azithromycin, Doxycycline, |
| | disorders of vagina (F) | ‹‹Levofloxacin›› |
| N94.10 | Unspecified dyspareunia (F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| N94.11 | Superficial (introital) dyspareunia (F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |
| N94.12 | Deep dyspareunia (F) | Azithromycin, Doxycycline, |
| | | ‹‹Levofloxacin›› |

Presumptive DX (Chlamydia) (continued)

| ICD-10-CM Code | Description | Medications + |
|----------------|--|----------------------------|
| N94.19 | Other specified dyspareunia (F) | Azithromycin, Doxycycline, |
| | | Levofloxacin |
| N94.89 | Other conditions associated with | Azithromycin, Doxycycline, |
| | female genital organs (F) | Levofloxacin |
| R30.0 | Dysuria (M/F) | Azithromycin, Doxycycline, |
| | | Levofloxacin |
| R30.9 | Painful micturition, unspecified (M/F) | Azithromycin, Doxycycline, |
| | | Levofloxacin |
| Z20.2 | STI (CT)-exposed partner (M/F) | Azithromycin, Doxycycline, |
| | | Levofloxacin |

«Epididymitis

| ICD-10-CM Code | Description | Medications |
|----------------|------------------------|---------------------------|
| N45.1 | Epdidymitis (M) | Ceftriaxone, Doxycycline |
| | | OR |
| | | Ceftriaxone, Levofloxacin |
| N45.3 | Epididymo-orchitis (M) | Ceftriaxone, Doxycycline |
| | | OR |
| | | Ceftriaxone, Levofloxacin |

Presumptive DX (Epididymitis)

| ICD-10-CM Code | Description | Medications + |
|----------------|---------------------------------|-----------------------------|
| N50.811 | Right testicular pain (M) | Ceftriaxone, Doxycycline |
| | | OR |
| | | Ceftriaxone, Levofloxacin |
| N50.812 | Left testicular pain (M) | Ceftriaxone, Doxycycline |
| | | OR |
| | | Ceftriaxone, Levofloxacin |
| N50.819 | Testicular pain unspecified (M) | Ceftriaxone, Doxycycline |
| | | OR |
| | | Ceftriaxone, Levofloxacin>> |

Gonorrhea

| ICD-10-CM Code | Description | Medications + |
|----------------|---|------------------------------|
| A54.01 | GC cystitis and urethritis, unspecified | R: Cefriaxone |
| | (M/F) | A: Cefixime |
| | | A: If cephalosporin allergy: |
| | | Gentamicin plus |
| | | Azithromycin |
| A54.5 | GC pharyngitis (M/F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| A54.6 | GC anus/rectum (M/F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| A54.22 | GC prostatitis (M) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| A54.03 | GC cervicitis, unspecified (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |

Presumptive DX (Gonorrhea)

| ICD-10-CM Code | Description | Medications + |
|----------------|--|-------------------------|
| N34.2 | Other urethritis (M) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N45.3 | Epididymo-orchitis (M) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N72 | Inflammatory disease of cervix uteri (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N89.8 | Other specified non-inflammatory | Azithromycin, Cefixime, |
| | disorders of vagina (F) | Ceftriaxone, Gentamicin |

Presumptive DX (Gonorrhea) (continued)

| ICD-10-CM Code | Description | Medications = |
|----------------|---|-------------------------|
| N94.10 | Unspecified dyspareunia (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N94.11 | Superficial (introital) dyspareunia (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N94.12 | Deep dyspareunia (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N94.19 | Other specified dyspareunia (F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| N94.89 | Other conditions associated with | Azithromycin, Cefixime, |
| | female genital organs (F) | Ceftriaxone, Gentamicin |
| R30.0 | Dysuria (M/F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| R30.9 | Painful micturition, unspecified (M/F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |
| Z20.2 | STI (GC)-exposed partner (M/F) | Azithromycin, Cefixime, |
| | | Ceftriaxone, Gentamicin |

Nongonococcal Urethritis (NGU)

| ICD-10-CM Code | Description | Medications + |
|----------------|----------------------------|-----------------|
| N34.1 | Nonspecific urethritis (M) | R: Doxycycline |
| | | A: Azithromycin |

Herpes (Genital Only)

| ICD-10-CM Code | Description | Medications + |
|----------------|--------------------|---------------|
| A60.01 | Herpes penis | Acyclovir |
| A60.04 | HSV Vulvovaginitis | Acyclovir |

Presumptive DX (Herpes, Genital Only)

| ICD-10-CM Code | Description | Medications = |
|----------------|---------------------|---------------|
| N48.5 | Ulcer of penis | Acyclovir |
| N76.6 | Ulceration of vulva | Acyclovir |

Pelvic Inflammatory Disease (PID-Uncomplicated Outpatient Only)

| ICD-10-CM Code | Description | Medications + |
|----------------|---|--------------------------------|
| N70.03 | Acute salpingitis and oophoritis | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |
| N70.93 | Salpingitis and oophoritis, unspecified | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |
| N94.10 | Unspecified dyspareunia (F) | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |

Pelvic Inflammatory Disease (PID-Uncomplicated Outpatient Only) (continued)

| ICD-10-CM Code | Description | Medications + |
|----------------|---|--------------------------------|
| N94.11 | Superficial (introital) dyspareunia (F) | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |
| N94.12 | Deep dyspareunia (F) | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |
| N94.19 | Other specified dyspareunia (F) | R: Ceftriaxone injection, plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |
| N94.89 | Other conditions associated with | R: Ceftriaxone injection, plus |
| | female genital organs (F) | Doxycycline with |
| | | Metronidazole |
| | | R: Cefoxitin injection and |
| | | Probenecid plus |
| | | Doxycycline with |
| | | Metronidazole |
| | | A: Levofloxacin with |
| | | Metronidazole |

Syphilis

| ICD-10-CM Code | Description | Medications = |
|----------------|---------------------------|------------------------------|
| A51.0 | Primary genital (M/F) | Penicillin G benzathine long |
| | | acting – injection † |
| A51.31 | Condyloma latum (M/F) | Penicillin G benzathine long |
| | | acting – injection † |
| A51.39 | Other, secondary (M/F) | Penicillin G benzathine long |
| | | acting – injection † |
| A51.5 | Early, latent (M/F) | Penicillin G benzathine long |
| | | acting – injection † |
| A52.8 | Late, latent (M/F) | Penicillin G benzathine long |
| | | acting – injection † |
| A53.0 | Latent, unspecified (M/F) | Penicillin G benzathine long |
| | | acting – injection † |

Presumptive DX (Syphilis)

| ICD-10-CM Code | Description | Medications + |
|----------------|----------------------------------|------------------------------|
| N48.5 | Ulcer of penis | Penicillin G benzathine long |
| | | acting – injection † |
| N76.6 | Ulceration of vulva | Penicillin G benzathine long |
| | | acting – injection † |
| Z20.2 | STI (Syphilis) – exposed partner | Penicillin G benzathine long |
| | | acting – injection † |

Vaginal Candidiasis

| ICD-10-CM Code | Description | Medications + |
|----------------|---------------------------------------|----------------------------|
| B37.31 | Acute candidiasis of vulva and vagina | Clotrimazole, Fluconazole, |
| | _ | Miconazole, Terconazole |
| B37.32 | Chronic candidiasis of vulva and | Clotrimazole, Fluconazole, |
| | vagina | Miconazole, Terconazole € |

Bacterial Vaginosis

| ICD-10-CM Code | Description | Medications + |
|----------------|-----------------|----------------------------|
| N76.0 | Acute vaginitis | R: Metronidazole, |
| | _ | R: Clindamycin cream |
| | | A: Clindamycin capsules or |
| | | ovules |
| | | A: Secnidazole ‡ |
| | | A: Tinidazole |

Warts (Genital Only)

| ICD-10-CM Code | Description | Medications = |
|----------------|-----------------------------------|----------------------|
| A63.0 | Anogenital (venereal) warts (M/F) | Imiquimod, Podofilox |
| B08.1 | Molluscum (M/F) | Imiquimod, Podofilox |
| B07.9 | Viral wart, unspecified (M/F) | Imiguimod, Podofilox |

<u>Family Planning-Related Services: Management of Urinary Tract Infection (UTI)</u>

Treatment or diagnostic tests for the management of UTIs are covered when provided as part of, or as a follow-up to, a family planning visit where the UTI was identified or diagnosed. An additional ICD-10-CM code is required as noted below.

These benefits are for female clients only.

Urinary Tract Infection

| ICD-10-CM Code | Description | Medications + |
|----------------|-----------------------------------|---------------------------|
| N30.00 | Acute cystitis without hematuria | Cephalexin Ciprofloxacin, |
| | - | Nitrofurantoin, TMP/SMX |
| N30.01 | Acute cystitis with hematuria | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |
| R31.0 | Gross hematuria | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |
| R30.0 | Dysuria | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |
| R30.9 | Painful micturition, unspecified | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |
| R35.0 | Frequency of micturition | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |
| R10.30 | Lower abdominal pain, unspecified | Cephalexin Ciprofloxacin, |
| | | Nitrofurantoin, TMP/SMX |

Treatment and Dispensing Guidelines for Clinicians

Family Planning-Related Conditions Drug Regimens

Bacterial Vaginosis Treated with Metronidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--------------------|---------------------------|-----------------------------|---------------------|-----------------|
| 250 mg/500 mg tabs | 500 mg PO BID X 7 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |
| 0.75% vaginal gel | 5 g PV QHS X 5 days | 30 | Recommended regimen | S5000/ S5001 |

Bacterial Vaginosis Treated with Clindamycin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-----------------|-------------------|-------------------|-------------|----------------|
| 2% cream | 5 g PV X 7 days | 30 | Recommended | S5000/ |
| | | | regimen | S5001 |
| 150 mg capsules | 300 mg PO BID X 7 | 2 per | Alternative | S5000/ |
| | days | rolling 30 | regimen | S5001 |
| | | days | | |
| 100 mg ovules | 100 mg PV QHS X 3 | 30 | Alternative | S5000/ |
| _ | days | | regimen | S5001 |

Bacterial Vaginosis Treated with Tinidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--------------------|---------------------------|--------------------|-------------|----------------|
| 200 mg/500 mg tabs | 2 gm PO QD X 2 days, | 2 per | Alternative | S5000/ |
| | or 1 gm PO QD X 5 days | rolling 30 days | regimen | S5001 |

Chlamydia Treated with Doxycycline

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|--------------------------|-----------------------------|---------------------|-----------------|
| 100 mg tabs | 100 mg PO BID X 7days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |

Chlamydia Treated with Azithromycin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|----------------------|-------------|-----------------------------|---------------------|----------------|
| 500 mg tabs/1 gm pkt | 1 gm PO X 1 | 2 per rolling 30 days | Alternative regimen | Q0144 |

Chlamydia Treated with Levofloxacin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--------------------|--------------------------|-----------------------------|---------------------|-----------------|
| 250 mg/500 mg tabs | 500 mg PO QD X 7 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |

<u>Acute Epididymitis (most likely caused by GC, CT) Treated with Ceftriaxone plus Doxycycline</u>

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------------------|-------------------------|-----------------------------|---------------------|-----------------|
| Ceftriaxone 500 mg injection | 500 mg IM X 1 £ | 2 per rolling 30 days | Recommended regimen | J0696 |
| Doxycycline 100 mg tabs | 100 mg PO BID X 10 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |

Acute Epididymitis (most likely caused by GC, CT, or enteric organisms [men who practice insertive anal sex]) Treated with Ceftriaxone plus Levoflaxacin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------------------------|--------------------------|-----------------------------|---------------------|-----------------|
| Ceftriaxone 500 mg injection | 500 mg IM X 1 £ | 2 per rolling 30 days | Recommended regimen | J0696 |
| Levofloxacin 250 mg/500 mg tabs | 500 mg PO QD X 7 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |

Acute Epididymitis (most likely caused by enteric organisms only) Treated with Levofloxacin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------------------------|------------------------|-----------------------------|---------------------|-----------------|
| Levofloxacin 250 mg/500 mg tabs | 500 mg PO QD X 10 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |

External Genital Warts Treated with Imiquimod

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|---------------------|-------------------|-------------|----------------|
| 5% cream | QHS 3/week up to 16 | 30 | Recommended | S5000/ |
| | weeks | | regimen | S5001 |

External Genital Warts Treated with Podofilox

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------------|---|-------------------|---------------------|-------------------|
| 0.5% solution/gel | BID 3 days/week followed by 4 days no treatment, up to 4 weeks | 30 | Recommended regimen | \$5000/ \$5001 |

Genital Herpes Treated with Acyclovir

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|---------------------------------|-------------------|---------------------------------|-----------------|
| 400 mg tabs | 400 mg PO TID X 7 to 10 days | None | Primary herpes | S5000/ S5001 |
| 400 mg tabs | 800 mg PO BID X 5 days or | 30 | Recurrent herpes | S5000/ S5001 |
| 800 mg tabs | 800 mg PO TID X 2 days | | | |
| 400 mg tabs | 400 mg PO BID | 22 | Suppression of recurrent herpes | S5000/ S5001 |

Gonorrhea Treatment Notes

Refer to Note 1.

Gonorrhea Treated with Ceftriaxone

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------|---------------|-------------------|-------------|----------------|
| 500 mg injection | 500 mg IM X 1 | 15 | Recommended | J0696 |
| | | | regimen | |
| | | | (Note 1) | |

Gonorrhea Treated with Cefixime

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------|---------------|-------------------------|------------------------------|------------------|
| 400 mg tabs/caps | 800 mg PO X 1 | 2 per rolling day | Alternative regimen (Note 1) | S5000/ S50001 |

Nongonococcal Urethritis (NGU)

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|----------------------------|---------------------|-------------------|------------------------|-----------------|
| Doxycycline 100 mg tabs | 100 mg PO BID X 7 | None | Recommended | S5000/ S5001 |
| Azithromycin | days 1 gm PO X 1 | None | regimen Alternative | Q0144 |
| 500 mg tabs/1 gm packet | | | regimen | |

Recurrent/Persistent NGU due to Mycoplasma Genitalium Treated with Doxycycline followed by Moxifloxacin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------------------------|---------------------------|-------------------|---------------------|-----------------|
| Doxycycline 100 mg tabs | 100 mg PO BID X 7 days | None | Recommended regimen | S5000/ S5001 |
| Moxifloxacin 400 mg tabs β | 400 mg PO QD X 7 days | None | Recommended regimen | N/A |

Recurrent/Persistent NGU due to Mycoplasma genitalium Treated with Doxycycline followed by Azithromycin

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--|--|-------------------|---------------------|-----------------|
| Doxycycline 100 mg tabs | 100 mg PO BID X 7 days | None | Alternative regimen | S5000/ S5001 |
| Azithromycin 500 mg tabs/1 gm packet | 1 gm PO on day 1, then 500 mg PO QD X 3 days | None | Alternative regimen | Q0144 |

PID Treated with Ceftriaxone plus Doxycycline with Mentronidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|----------------------------------|----------------------------|-----------------------------|---------------------|-----------------|
| Ceftriaxone 250 mg injection | 500 mg IM X 1 | 2 per rolling 30 days | Recommended regimen | J0696 |
| Doxycycline 100 mg tabs | 100 mg PO BID X 14 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |
| Metronidazole 250/500 mg tabs | 500 mg PO BID X 14 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |

PID Treated with Cefoxitin and Probenecid, plus Doxycycline with Metronidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|----------------------------------|----------------------------|-----------------------------|---------------------|-------------------|
| Cefoxitin 1 gm injection | 2 gm IM X 1 | 2 per rolling 30 days | Recommended regimen | J0694 |
| Probenecid 500 mg tabs | 1 gm PO X 1 | 2 per rolling 30 days | Recommended regimen | J0694 |
| Doxycycline 100 mg tabs | 100 mg PO BID X 14 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |
| Metronidazole 250/500 mg tabs | 500 mg PO BID X 14 days | 2 per rolling 30 days | Recommended regimen | \$5000/ \$5001 |

PID Treated with Levofloxacin with Metronidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-----------------------------------|----------------------------|-----------------------------|---------------------|-----------------|
| Levofloxacin 250/500 mg tabs | 500 mg PO QD X 14 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |
| Metronidazole 250-/500 mg tabs | 500 mg PO BID X 14 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |

Syphilis (Primary, Secondary, Early Latent) Treated with Penicillin G Benzathine

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--|----------------------|-------------------|-----------------------|----------------|
| 1.2 mil units/2 ml 2.4 mil units/4 ml | 2.4 mil units IM X 1 | N/A | Recommended regimen † | J0561 |
| 2.4 IIIII UIIIIS/4 IIII | | | regimen r | |

Syphilis (Late Latent, Unknown Duration) Treated with Penicillin G Benzathine

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--------------------|-------------------------|-------------------|-------------|----------------|
| 1.2 mil units/2 ml | 2.4 mil units IM q week | N/A | Recommended | J0561 |
| 2.4 mil units/4 ml | X 3 doses | | regimen † | |

Trichomoniasis Treated with Metronidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|---------------------------|-----------------------------|-------------------------------|-----------------|
| 500 mg tabs | 2 gm PO X 1 | 2 per rolling 30 days | Recommended regimen (Males) | S5000/ S5001 |
| 500 mg tabs | 500 mg PO BID X 7 days | 2 per rolling 30 days | Recommended regimen (Females) | S5000/ S5001 |

Trichomoniasis Treated with Tinidazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-----------------|-------------|-------------------|----------------------------|-----------------|
| 250/500 mg tabs | 2 gm PO X 1 | 2 per rolling 30 | Alternative regimen (males | S5000/ S5001 |
| | | days | and females) | |

Urinary Tract Infection Reference

Refer to American Academy of Family Physicians, American Family Physician 2005; 72:451-6,458.

Urinary Tract Infection Treated with SMX/TMP DS

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-----------------|-------------------------------|-----------------------------|---------------------|-----------------|
| 800/160 mg tabs | 800/160 mg PO BID X 3 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |

Urinary Tract Infection Treated with SMX/TMP

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|----------------|--------------------------------|-------------------|---------------------|-----------------|
| 400/80 mg tabs | 400/80 mg 2 PO BID X 3 days | 2 per rolling 30 | Alternative regimen | S5000/ S5001 |
| | | days | | |

<u>Urinary Tract Infection Treated with Ciprofloxacin</u>

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|---------------------------|-----------------------------|---------------------|-----------------|
| 250 mg tabs | 250 mg PO BID X 3 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |
| 500 mg tabs | 500 mg PO QD X 3 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |

<u>Urinary Tract Infection Treated with Cephalexin</u>

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|---------------------------|-----------------------------|---------------------|-----------------|
| 500 mg caps | 500 mg PO BID X 7-10 days | 2 per rolling 30 days | Recommended regimen | S5000/ S5001 |
| 250 mg caps | 250 mg PO QID X 7-10 days | 2 per rolling 30 days | Alternative regimen | S5000/ S5001 |

Page updated: April 2024

<u>Urinary Tract Infection Treated with Nitrofurantoin</u>

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|--|------------------------|-----------------------------|---|---|
| <pre><<50 mg/100 mg caps>></pre> | 100 mg PO BID x 5 days | 2 per rolling 30 days | <pre><<recommended regimen="">></recommended></pre> | <pre><<s5000 s5001="">></s5000></pre> |

Vaginal Candidiasis Treated with Clotrimazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|-------------|----------------|-------------------|-------|-----------------|
| 2% cream ± | QHS for 3 days | 30 | N/A | S5000/ S5001 |
| 1% cream ± | QHS for 7 days | 30 | N/A | S5000/ S5001 |

Vaginal Candidiasis Treated with Fluconazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|---------------|----------------|-------------------|-------|-----------------|
| 150 mg tablet | Single dose PO | 30 | N/A | S5000/ S5001 |

Vaginal Candidiasis Treated with Miconazole

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|------------------------------|----------------|-------------------|-------|-----------------|
| 4% cream ± | QHS for 3 days | 30 | N/A | S5000/ S5001 |
| 2% cream ± | QHS for 7 days | 30 | N/A | S5000/ S5001 |
| 200 mg vaginal suppository ± | QHS for 3 days | 30 | N/A | S5000/ S5001 |
| 100 mg vaginal suppository ± | QHS for 7 days | 30 | N/A | S5000/ S5001 |

Vaginal Candidiasis Treated with Terconazole

Terconazole is reserved for use in complicated cases of Vaginal Candidiasis. Terconazole is restricted to Pharmacy dispensing only; for use after treatment failure with other anti-fungals. A *Treatment Authorization Request* (TAR) is required.

| Dosage Size | Regimens* | Fill Freq Days | Notes | Clinic Code |
|---------------------|----------------|-------------------|-------|-----------------|
| 80 mg suppository ± | QHS for 3 days | 30 | N/A | S5000/ S5001 |
| 0.8% cream ± | QHS for 3 days | 30 | N/A | S5000/ S5001 |
| 0.4% cream ± | QHS for 7 days | 30 | N/A | N/A |

Legend

Symbols used in the document above are explained in the following table.

| Symbol | Description |
|-----------|--|
| ((| This is a change mark symbol. It is used to indicate where on the page the most recent change begins. |
| >> | This is a change mark symbol. It is used to indicate where on the page the most recent change ends. |
| # | Only dosage regimens included in current CDC STI Treatment Guidelines or California STI Treatment Guidelines may be used. Refer to www.cdc.gov and www.cdc.gov and www.cdc.gov and www.c |
| € | Restricted to pharmacy dispensing only; for use after treatment failure with other anti-fungals, TAR required. |
| * | CDC, Sexually Transmitted Infections Treatment Guidelines, 2021, MMWR July 2021:70(4): 1-192. |
| ± | Oil-based products may weaken latex condoms and diaphragms. |
| † | For nonpregnant persons with penicillin allergy who have primary or secondary syphilis, may treat with doxycycline 100 mg orally 2 times per day for 14 days. For those with late latent or syphilis of unknown duration, may treat with 100 mg orally 2 times per day for 28 days. |
| ‡ | For pharmacy dispensing only. |
| £ | For persons weighing more than 150 kg (330 lbs), ceftriaxone 1g IM should be administered. |
| β | Moxifloxacin is for pharmacy dispensing only. |

Legend (continued)

Symbols used in the document above are explained in the following table.

| Symbol | Description |
|--------|--|
| Note 1 | The CDC Sexually Transmitted Infections: Treatment Guidelines, 2021 recommends: |
| | For uncomplicated gonococcal infections of the cervix, urethra, or rectum: treat with a single dose of ceftriaxone 500 mg IM for persons weighing less than 150 kg (330 lbs). For persons weighing more than 150 kg (330 lbs), ceftriaxone 1 g IM should be administered. If chlamydial infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days. |
| | If treating with cefixime, and chlamydial infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg orally twice daily for 7 days. |
| | For patients with significant anaphylaxis-type allergies to penicillin or allergies to cephalosporins, providers should treat with gentamicin 240 mg IM (onsite dispensing only with HCPCS code J1580; requires a TAR) with azithromycin 2 gm PO X 1. |
| | For uncomplicated gonococcal infections of the pharynx: treat with ceftriaxone, as noted above. |
| | If chlamydia coinfection is identified when pharyngeal gonorrhea testing is performed, providers should treat for chlamydia with doxycycline 100 mg orally twice a day for 7 days. |